Suven Pharmaceuticals: June '22 Results Update : vimarsana.com

Suven Pharmaceuticals’ (Suven’s) Q1FY22-23 revenue was up by 28% y-o-y (year-on-year) to Rs339 crore, aided by growth in pharma and specialty chemicals CDMO (contract development and manufacturing organisation) segment.

Related Keywords

, Suven Pharmaceutical , Mutual Fund Returns , Ank Fixed Deposits , Tocks , Hares , Nvestor Returns , Ortfolio Allocation ,